Skip to main content
[Preprint]. 2021 Dec 20:2021.12.16.472155. [Version 1] doi: 10.1101/2021.12.16.472155

Figure 1.

Figure 1.

Characterization of entrectinib and vandetanib. SARS-CoV-2 inhibition in A549-ACE2 cell lines and cytotoxicity of A) remdesivir B) entrectinib and C) vandetanib. D) EC90 and CC50 values for entrectinib and vandetanib (strain USA_WA1/2020) in Caco-2 cells. Only VYR data was reported. E) HCoV229E antiviral assay and in Huh-7 cell line with entrectinib and F) vandetanib. G) MicroScale Thermophoresis binding analysis for the interaction between SARS-CoV-2 Spike RBD and entrectinib. H) Pseudo SARS-CoV-2 D614G baculovirus (Montana Molecular #C1110G, #C1120G) assay in presence of vandetanib at 1 μM and its I) graphical analysis.